Combat Medical, a medical device company focused on improving the delivery and effectiveness of cancer therapeutics, announced it has raised £2.6 million in the first close of a Series A financing round. The investment will support the development and regulatory advancement of the company’s hyperthermic intravesical chemotherapy technology for treating BCG-unresponsive non-muscle-invasive bladder cancer.
The round was led by the T&J Meyer Family Foundation, with participation from Varia Ventures, NW Angel Fund, and several non-institutional family offices and individual investors.
The new funding will help advance Combat Medical’s HIVEC HEAT clinical trial, a pivotal phase 3 study designed to support FDA registration of the company’s HIVEC therapy. The trial is evaluating the safety and effectiveness of the treatment in patients with BCG-unresponsive non-muscle-invasive bladder cancer, a group that currently faces limited options beyond radical cystectomy, the surgical removal of the bladder.
HIVEC is designed to enhance chemotherapy delivery by heating the therapeutic agents before they are administered directly into the bladder. This hyperthermic approach aims to increase treatment efficacy while maintaining tolerability, offering a potential bladder-sparing alternative to invasive surgery.
According to the company, its technology already has a significant installed base, with more than 350 systems deployed globally and more than 100,000 HIVEC treatments performed to date.
Combat Medical plans to use future financings to complete FDA registration and expand operations as it prepares for broader commercialization, particularly in the United States. The company also intends to advance additional clinical programs using its hyperthermic technology platform, including treatments for advanced bladder cancer and peritoneal cancer.
If successful, the technology could help reshape treatment pathways for patients with difficult-to-treat bladder cancers by providing clinicians with a more accessible and potentially less invasive therapeutic option.
KEY QUOTES:
“Our installed base of over 350 systems and the completion of over 100,000 HIVEC treatments to date demonstrates efficacy and use as a safe and well-tolerated, bladder-sparing alternative to radical cystectomy in BCG-unresponsive, high-risk NMIBC. Setting a new standard for patient care, it also provides clinicians and payers with advanced, affordable options that can easily be built into current treatment pathways. We are proud to have our investors on board as we progress through to FDA approval.”
Edward Bruce-White, Chief Executive Officer of Combat Medical
“Combat Medical is leading the development and clinical use of device assisted therapies with potential to disrupt current treatment standards. With systems in wide clinical use and already impacting patient outcomes, we are excited to support the company as HIVEC progresses through clinical trials.”
Balint Nemeth, T&J Meyer Family Foundation
